Summary
BeOne Medicines Ltd. reported a strong second quarter for 2025, demonstrating significant year-over-year revenue growth driven by its key oncology products. Total revenues increased by 41.6% to $1.32 billion, primarily fueled by a 41.4% rise in product revenue, with BRUKINSA® sales alone surging 49.0% to $950 million globally. This robust top-line growth, coupled with improving gross margins and disciplined operating expense management, allowed the company to achieve a positive GAAP net income of $94.3 million, a substantial improvement from the net loss in the prior year's comparable period. The company also highlighted significant progress in its pipeline, anticipating over 20 R&D milestones in the next 18 months. Operationally, BeOne Medicines is effectively scaling its commercial capabilities, particularly in the U.S. and Europe, which are key drivers for BRUKINSA's continued market leadership. The company's strategic focus on expanding its oncology franchise is evident in its R&D day announcements and positive clinical development updates. While R&D and SG&A expenses increased to support this growth, they were managed effectively relative to revenue growth, leading to improved operating leverage and a shift from an operating loss to an operating profit. The company also successfully completed its redomiciliation to Switzerland and updated its name, marking a significant corporate milestone.
Financial Highlights
48 data points| Revenue | $1.32B |
| Gross Profit | $1.15B |
| R&D Expenses | $524.90M |
| SG&A Expenses | $537.91M |
| Operating Expenses | $1.06B |
| Operating Income | $87.89M |
| Interest Expense | $12.05M |
| Net Income | $94.32M |
| EPS (Basic) | $0.07 |
| EPS (Diluted) | $0.06 |
| Shares Outstanding (Basic) | 1.41B |
| Shares Outstanding (Diluted) | 1.46B |
Key Highlights
- 1Total revenues increased by 41.6% to $1.32 billion for Q2 2025 compared to Q2 2024.
- 2Global BRUKINSA® revenues grew by 49.0% to $950 million in Q2 2025.
- 3Achieved positive GAAP net income of $94.3 million for Q2 2025, a significant turnaround from a net loss in Q2 2024.
- 4Gross margin on product sales improved to 87.4% in Q2 2025 from 85.0% in Q2 2024.
- 5Research and Development expenses increased by 15.5% to $524.9 million, supporting pipeline advancement.
- 6Selling, General, and Administrative expenses increased by 21.2% to $537.9 million, reflecting investment in global commercial expansion.
- 7The company anticipates over 20 R&D milestones in the next 18 months.
- 8Completed redomiciliation to Switzerland and changed its legal name to BeOne Medicines Ltd. on May 27, 2025.